U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

ribavirin response - Efficacy

MedGen UID:
1003282
•Concept ID:
CN322749
•
Sign or Symptom

Professional guidelines

PubMed

Prevention and management of treatment failure to new oral hepatitis C drugs.
Benítez-Gutiérrez L, Barreiro P, Labarga P, de Mendoza C, Fernandez-Montero JV, Arias A, Peña JM, Soriano V
Expert Opin Pharmacother 2016 Jun;17(9):1215-23. Epub 2016 May 9 doi: 10.1080/14656566.2016.1182156. PMID: 27149603
New prospects for the treatment and prevention of hepatitis C in children.
Ohmer S, Honegger J
Curr Opin Pediatr 2016 Feb;28(1):93-100. doi: 10.1097/MOP.0000000000000313. PMID: 26709684Free PMC Article
HCV and HIV co-infection: mechanisms and management.
Chen JY, Feeney ER, Chung RT
Nat Rev Gastroenterol Hepatol 2014 Jun;11(6):362-71. Epub 2014 Feb 18 doi: 10.1038/nrgastro.2014.17. PMID: 24535328Free PMC Article

Recent clinical studies

Etiology

Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review.
Falade-Nwulia O, Suarez-Cuervo C, Nelson DR, Fried MW, Segal JB, Sulkowski MS
Ann Intern Med 2017 May 2;166(9):637-648. Epub 2017 Mar 21 doi: 10.7326/M16-2575. PMID: 28319996Free PMC Article
Safety and efficacy of sofosbuvir plus ledipasvir with and without ribavirin for chronic HCV genotype-1 infection: a systematic review and meta-analysis.
Ahmed H, Elgebaly A, Abushouk AI, Hammad AM, Attia A, Negida A
Antivir Ther 2017;22(5):369-379. Epub 2016 Sep 2 doi: 10.3851/IMP3083. PMID: 27588749
Efficacy and safety of elbasvir/grazoprevir and sofosbuvir/pegylated interferon/ribavirin: A phase III randomized controlled trial.
Sperl J, Horvath G, Halota W, Ruiz-Tapiador JA, Streinu-Cercel A, Jancoriene L, Werling K, Kileng H, Koklu S, Gerstoft J, Urbanek P, Flisiak R, Leiva R, Kazenaite E, Prinzing R, Patel S, Qiu J, Asante-Appiah E, Wahl J, Nguyen BY, Barr E, Platt HL
J Hepatol 2016 Dec;65(6):1112-1119. Epub 2016 Aug 16 doi: 10.1016/j.jhep.2016.07.050. PMID: 27542322
Telaprevir user's guide.
Liapakis AM, Jacobson I
Liver Int 2012 Feb;32 Suppl 1:17-25. doi: 10.1111/j.1478-3231.2011.02708.x. PMID: 22212567
Guidelines for stopping therapy in chronic hepatitis C.
Russo MW, Fried MW
Curr Gastroenterol Rep 2004 Feb;6(1):17-21. doi: 10.1007/s11894-004-0021-6. PMID: 14720449

Diagnosis

Genotype 3-hepatitis C virus' last line of defense.
Zarębska-Michaluk D
World J Gastroenterol 2021 Mar 21;27(11):1006-1021. doi: 10.3748/wjg.v27.i11.1006. PMID: 33776369Free PMC Article
Meta-Analysis of Grazoprevir plus Elbasvir for Treatment of Hepatitis C Virus Genotype 1 Infection.
Ahmed H, Abushouk AI, Menshawy A, Attia A, Mohamed A, Negida A, Abdel-Daim MM
Ann Hepatol 2018 January-February;17(1):18-32. doi: 10.5604/01.3001.0010.7532. PMID: 29311409
Sofosbuvir and velpatasvir for the treatment of hepatitis C.
Jackson WE, Everson GT
Expert Rev Gastroenterol Hepatol 2017 Jun;11(6):501-505. Epub 2017 May 11 doi: 10.1080/17474124.2017.1326817. PMID: 28468532
The role of interferon in the new era of hepatitis C treatments.
Parekh PJ, Shiffman ML
Expert Rev Gastroenterol Hepatol 2014 Aug;8(6):649-56. Epub 2014 Apr 23 doi: 10.1586/17474124.2014.910453. PMID: 24758387
Improving anti-hepatitis C virus therapy.
Pol S, Mallet VO
Expert Opin Biol Ther 2006 Sep;6(9):923-33. doi: 10.1517/14712598.6.9.923. PMID: 16918259

Therapy

Pharmacodynamic and pharmacokinetic evaluation of the combination of daclatasvir/sofosbuvir/ribavirin in the treatment of chronic hepatitis C.
Rivero-Juarez A, Brieva T, Frias M, Rivero A
Expert Opin Drug Metab Toxicol 2018 Sep;14(9):901-910. Epub 2018 Aug 2 doi: 10.1080/17425255.2018.1506765. PMID: 30058394
Statin therapy improves response to interferon alfa and ribavirin in chronic hepatitis C: a systematic review and meta-analysis.
Zhu Q, Li N, Han Q, Zhang P, Yang C, Zeng X, Chen Y, Lv Y, Liu X, Liu Z
Antiviral Res 2013 Jun;98(3):373-9. Epub 2013 Apr 16 doi: 10.1016/j.antiviral.2013.04.009. PMID: 23603497
Telaprevir user's guide.
Liapakis AM, Jacobson I
Liver Int 2012 Feb;32 Suppl 1:17-25. doi: 10.1111/j.1478-3231.2011.02708.x. PMID: 22212567
Pharmacokinetics and pharmacodynamics of peginterferon and ribavirin: implications for clinical efficacy in the treatment of chronic hepatitis C.
Noureddin M, Ghany MG
Gastroenterol Clin North Am 2010 Sep;39(3):649-58. doi: 10.1016/j.gtc.2010.08.008. PMID: 20951922Free PMC Article
Role of ribavirin in HCV treatment response: now and in the future.
Jain MK, Zoellner C
Expert Opin Pharmacother 2010 Mar;11(4):673-83. doi: 10.1517/14656560903580001. PMID: 20163278

Prognosis

Treatment Outcomes of Sofosbuvir/Velpatasvir/Voxilaprevir in Direct-Acting Antiviral-Experienced Hepatitis C Virus Patients: A Systematic Review and Meta-Analysis.
Devan P, Tiong KLA, Neo JE, Mohan BP, Wijarnpreecha K, Tam YCS, Coppola N, Preda CM, Wong YJ
Viruses 2023 Jun 30;15(7) doi: 10.3390/v15071489. PMID: 37515176Free PMC Article
Viral and host factors associated with outcomes of hepatitis C virus infection (Review).
Yan Z, Wang Y
Mol Med Rep 2017 May;15(5):2909-2924. Epub 2017 Mar 22 doi: 10.3892/mmr.2017.6351. PMID: 28339063
Boceprevir in liver transplant recipients.
Saab S, Manne V, Bau S, Reynolds JA, Allen R, Goldstein L, Durazo F, El-Kabany M, Han S, Busuttil RW
Liver Int 2015 Jan;35(1):192-7. Epub 2014 Apr 11 doi: 10.1111/liv.12548. PMID: 24673728
Sustained virological response and baseline predictors in HIV-HCV coinfected patients retreated with pegylated interferon and ribavirin after failing a previous interferon-based therapy: systematic review and meta-analysis.
Basso M, Parisi SG, Mengoli C, Gentilini V, Menegotto N, Monticelli J, Nicolè S, Cruciani M, Palù G
HIV Clin Trials 2013 Jul-Aug;14(4):127-39. doi: 10.1310/hct1404-127. PMID: 23924585
Guidelines for stopping therapy in chronic hepatitis C.
Russo MW, Fried MW
Curr Gastroenterol Rep 2004 Feb;6(1):17-21. doi: 10.1007/s11894-004-0021-6. PMID: 14720449

Clinical prediction guides

Treatment Outcomes of Sofosbuvir/Velpatasvir/Voxilaprevir in Direct-Acting Antiviral-Experienced Hepatitis C Virus Patients: A Systematic Review and Meta-Analysis.
Devan P, Tiong KLA, Neo JE, Mohan BP, Wijarnpreecha K, Tam YCS, Coppola N, Preda CM, Wong YJ
Viruses 2023 Jun 30;15(7) doi: 10.3390/v15071489. PMID: 37515176Free PMC Article
Efficacy and Safety of Ledispavir/Sofosbuvir with or without Ribavirin in patients with Decompensated Liver Cirrhosis and Hepatitis C Infection: a Cohort Study.
Gheorghe LS, Preda C, Iliescu L, Istratescu D, Chifulescu AE, Pop CS, Trifan A, Stanciu C, Diculescu M, Voiosu T, Baicus C, Tugui L, Iacob S, Tieranu C, Meianu C, Manuc M
J Gastrointestin Liver Dis 2020 Sep 9;29(3):385-390. doi: 10.15403/jgld-2448. PMID: 32919421
Viral and host factors associated with outcomes of hepatitis C virus infection (Review).
Yan Z, Wang Y
Mol Med Rep 2017 May;15(5):2909-2924. Epub 2017 Mar 22 doi: 10.3892/mmr.2017.6351. PMID: 28339063
Safety and efficacy of peginterferon alpha plus ribavirin in patients with chronic hepatitis C and coexisting heart disease.
Durante-Mangoni E, Iossa D, Pinto D, De Vincentiis L, Ragone E, Utili R
Dig Liver Dis 2011 May;43(5):411-5. doi: 10.1016/j.dld.2010.12.011. PMID: 21310673
Improving anti-hepatitis C virus therapy.
Pol S, Mallet VO
Expert Opin Biol Ther 2006 Sep;6(9):923-33. doi: 10.1517/14712598.6.9.923. PMID: 16918259

Recent systematic reviews

The efficacy and safety of direct-acting antiviral regimens for end-stage renal disease patients with HCV infection: a systematic review and network meta-analysis.
Chen R, Xiong Y, Zeng Y, Wang X, Xiao Y, Zheng Y
Front Public Health 2023;11:1179531. Epub 2023 Sep 29 doi: 10.3389/fpubh.2023.1179531. PMID: 37841743Free PMC Article
Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with or without Ribavirin for Treatment of Hepatitis C Virus Genotype 1: A Systematic Review and Meta-analysis.
Ahmed H, Abushouk AI, Menshawy A, Mohamed A, Negida A, Loutfy SA, Abdel-Daim MM
Clin Drug Investig 2017 Nov;37(11):1009-1023. doi: 10.1007/s40261-017-0565-5. PMID: 28871475
The Efficacy and Safety of 12 Weeks of Sofosbuvir and Ledipasvir versus Sofosbuvir, Ledipasvir, and Ribavirin in Patients with Chronic Hepatitis C, Genotype 1, Who Have Cirrhosis and Have Failed Prior Therapy: A Systematic Review and Meta-Analysis.
Stokes W, Fenton C, Clement F, James M, Ronksley P, Tang KL
Can J Gastroenterol Hepatol 2017;2017:6468309. Epub 2017 Mar 6 doi: 10.1155/2017/6468309. PMID: 28367429Free PMC Article
Safety and efficacy of sofosbuvir plus ledipasvir with and without ribavirin for chronic HCV genotype-1 infection: a systematic review and meta-analysis.
Ahmed H, Elgebaly A, Abushouk AI, Hammad AM, Attia A, Negida A
Antivir Ther 2017;22(5):369-379. Epub 2016 Sep 2 doi: 10.3851/IMP3083. PMID: 27588749
Role of ribavirin in HCV treatment response: now and in the future.
Jain MK, Zoellner C
Expert Opin Pharmacother 2010 Mar;11(4):673-83. doi: 10.1517/14656560903580001. PMID: 20163278

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Consumer resources

    Reviews

    Related information

    • ClinVar
      Related medical variations
    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...